Abeona CEO sells 56,344 shares for tax obligations

Abeona Therapeutics CEO Vishwas Seshadri reported selling a total of 56,344 shares of common stock in open-market transactions on June 8 and 9, 2026.

Accepted by SEC EDGAR 06/09/2026 - 08:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Abeona Therapeutics CEO Vishwas Seshadri reported selling a total of 56,344 shares of common stock in open-market transactions on June 8 and 9, 2026. According to the disclosure, these sales were made to cover tax obligations associated with the vesting of restricted stock awards.

After these tax-related sales, Seshadri directly owns 1,374,079 shares of Abeona Therapeutics common stock.

Insider Trade Summary

Net Seller: 56,344 shares

Net Sell 2 txns

Insider Seshadri Vishwas

Role Chief Executive Officer

Sold 56,344 shs ($302K)

Share of Position Sold 3.9%

Type	Security	Shares	Price	Value
Sale	Common Stock	31,916	$5.3042	$169K
Sale	Common Stock	24,428	$5.4295	$133K

Holdings After Transaction: Common Stock — 1,374,079 shares (Direct)

Holdings Before and After: Common Stock, 1,430,423 to 1,374,079 shares (Direct)

Other Insiders: 5 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (3)

1. F1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Key Figures

Total shares sold: 56,344 shares Shares sold on June 9, 2026: 31,916 shares Shares sold on June 8, 2026: 24,428 shares +3 more

6 metrics

Total shares sold 56,344 shares Open-market sales on June 8–9, 2026

Shares sold on June 9, 2026 31,916 shares Common stock at $5.3042 weighted average

Shares sold on June 8, 2026 24,428 shares Common stock at $5.4295 weighted average

Shares held after transactions 1,374,079 shares CEO direct ownership after June 2026 sales

Price range June 9 sales $5.24–$5.47 Multiple trades; weighted average reported

Price range June 8 sales $5.345–$5.54 Multiple trades; weighted average reported

Key Terms

restricted stock awards, weighted average price, open-market sale, Form 4, +1 more

5 terms

restricted stock awards financial

"to cover tax obligations associated with the vesting of restricted stock awards"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sale reported in this Form 4 was to cover tax obligations"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

transaction code "S" regulatory

"transaction_code": "S""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Abeona Therapeutics (ABEO) report for its CEO?

Abeona Therapeutics reported that CEO Vishwas Seshadri sold 56,344 shares of common stock. The transactions occurred on June 8 and 9, 2026 and were disclosed on Form 4 as open-market sales linked to restricted stock vesting tax obligations.

Why did the Abeona (ABEO) CEO sell 56,344 shares of common stock?

The company disclosed that the CEO’s share sales were to cover tax obligations from vesting restricted stock awards. This means the transactions were tied to compensation-related tax liabilities rather than a discretionary reduction in overall equity exposure.

How many Abeona Therapeutics (ABEO) shares does the CEO hold after the reported sales?

Following the reported transactions, CEO Vishwas Seshadri directly holds 1,374,079 shares of Abeona common stock. This post-transaction figure reflects his remaining equity position after selling 56,344 shares to satisfy tax obligations.

At what prices did the Abeona (ABEO) CEO sell his shares in the Form 4 filing?

The CEO’s reported sales occurred at weighted average prices around $5.43 and $5.30 per share. Individual trades were executed within disclosed ranges between $5.24 and $5.54, as detailed in the Form 4 transaction footnotes.

Were the Abeona Therapeutics (ABEO) CEO’s share sales open-market transactions?

Yes, the Form 4 classifies both transactions as open-market sales of common stock. They are coded with transaction code "S," indicating sales in the open market or private transactions, and are specifically linked to covering restricted stock vesting taxes.

Does the Abeona (ABEO) Form 4 mention restricted stock awards for the CEO?

Yes, the filing states the sales were to cover tax obligations from vesting restricted stock awards. This clarifies that the transactions are connected to equity compensation vesting events rather than a standalone liquidation of the CEO’s shareholdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seshadri Vishwas

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OHIO 44103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/08/2026		S(1)		24,428	D	$5.4295(2)	1,405,995	D
Common Stock	06/09/2026		S(1)		31,916	D	$5.3042(3)	1,374,079	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.345 to $5.54 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.47 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Vishwas Seshadri	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)